Lazard Asset Management LLC Increases Stock Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Lazard Asset Management LLC increased its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 22.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 88,493 shares of the company's stock after acquiring an additional 15,996 shares during the quarter. Lazard Asset Management LLC owned about 0.18% of Prestige Consumer Healthcare worth $6,909,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PBH. Kestra Investment Management LLC bought a new position in Prestige Consumer Healthcare in the 4th quarter worth $27,000. CIBC Private Wealth Group LLC increased its position in shares of Prestige Consumer Healthcare by 48.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock valued at $34,000 after buying an additional 152 shares during the period. Headlands Technologies LLC bought a new position in Prestige Consumer Healthcare in the fourth quarter worth about $40,000. Johnson Financial Group Inc. purchased a new stake in Prestige Consumer Healthcare in the fourth quarter worth about $93,000. Finally, Huntington National Bank boosted its position in Prestige Consumer Healthcare by 133.2% during the 4th quarter. Huntington National Bank now owns 1,481 shares of the company's stock valued at $116,000 after acquiring an additional 846 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Stock Down 0.6%

Shares of NYSE:PBH traded down $0.51 on Tuesday, hitting $88.43. 107,286 shares of the company traded hands, compared to its average volume of 294,204. The stock has a 50 day simple moving average of $83.37 and a 200-day simple moving average of $82.04. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. The company has a market cap of $4.37 billion, a PE ratio of 20.70, a PEG ratio of 2.69 and a beta of 0.44. Prestige Consumer Healthcare Inc. has a 52 week low of $62.35 and a 52 week high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $1.32 earnings per share for the quarter, beating analysts' consensus estimates of $1.30 by $0.02. The business had revenue of $296.52 million during the quarter, compared to analyst estimates of $289.36 million. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Prestige Consumer Healthcare's revenue was up 7.0% compared to the same quarter last year. During the same period last year, the business earned $1.02 EPS. As a group, research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the sale, the senior vice president now directly owns 17,157 shares in the company, valued at approximately $1,544,130. This trade represents a 8.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on PBH shares. StockNews.com raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Saturday. DA Davidson upped their price target on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Canaccord Genuity Group increased their price objective on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a report on Friday, February 7th. Royal Bank of Canada upgraded shares of Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. Finally, Oppenheimer upped their target price on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a research report on Thursday, February 13th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $93.33.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.